93 related articles for article (PubMed ID: 21750962)
1. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.
Vuorela M; Pylkäs K; Hartikainen JM; Sundfeldt K; Lindblom A; von Wachenfeldt Wäppling A; Haanpää M; Puistola U; Rosengren A; Anttila M; Kosma VM; Mannermaa A; Winqvist R
Breast Cancer Res Treat; 2011 Dec; 130(3):1003-10. PubMed ID: 21750962
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer.
Torres-Esquius S; Llop-Guevara A; Gutiérrez-Enríquez S; Romey M; Teulé À; Llort G; Herrero A; Sánchez-Henarejos P; Vallmajó A; González-Santiago S; Chirivella I; Cano JM; Graña B; Simonetti S; Díaz de Corcuera I; Ramon Y Cajal T; Sanz J; Serrano S; Otero A; Churruca C; Sánchez-Heras AB; Servitja S; Guillén-Ponce C; Brunet J; Denkert C; Serra V; Balmaña J
JAMA Netw Open; 2024 Apr; 7(4):e247811. PubMed ID: 38648056
[TBL] [Abstract][Full Text] [Related]
3. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.
Yang X; Song H; Leslie G; Engel C; Hahnen E; Auber B; Horváth J; Kast K; Niederacher D; Turnbull C; Houlston R; Hanson H; Loveday C; Dolinsky JS; LaDuca H; Ramus SJ; Menon U; Rosenthal AN; Jacobs I; Gayther SA; Dicks E; Nevanlinna H; Aittomäki K; Pelttari LM; Ehrencrona H; Borg Å; Kvist A; Rivera B; Hansen TVO; Djursby M; Lee A; Dennis J; Bowtell DD; Traficante N; Diez O; Balmaña J; Gruber SB; Chenevix-Trench G; Investigators K; Jensen A; Kjær SK; Høgdall E; Castéra L; Garber J; Janavicius R; Osorio A; Golmard L; Vega A; Couch FJ; Robson M; Gronwald J; Domchek SM; Culver JO; de la Hoya M; Easton DF; Foulkes WD; Tischkowitz M; Meindl A; Schmutzler RK; Pharoah PDP; Antoniou AC
J Natl Cancer Inst; 2020 Dec; 112(12):1242-1250. PubMed ID: 32107557
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
Gayarre J; Martín-Gimeno P; Osorio A; Paumard B; Barroso A; Fernández V; de la Hoya M; Rojo A; Caldés T; Palacios J; Urioste M; Benítez J; García MJ
Br J Cancer; 2017 Sep; 117(7):1048-1062. PubMed ID: 28829762
[TBL] [Abstract][Full Text] [Related]
5. Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
Hu C; Nagaraj AB; Shimelis H; Montalban G; Lee KY; Huang H; Lumby CA; Na J; Susswein LR; Roberts ME; Marshall ML; Hiraki S; LaDuca H; Chao E; Yussuf A; Pesaran T; Neuhausen SL; Haiman CA; Kraft P; Lindstrom S; Palmer JR; Teras LR; Vachon CM; Yao S; Ong I; Nathanson KL; Weitzel JN; Boddicker N; Gnanaolivu R; Polley EC; Mer G; Cui G; Karam R; Richardson ME; Domchek SM; Yadav S; Hruska KS; Dolinsky J; Weroha SJ; Hart SN; Simard J; Masson JY; Pang YP; Couch FJ
Cancer Res; 2023 Aug; 83(15):2557-2571. PubMed ID: 37253112
[TBL] [Abstract][Full Text] [Related]
6. BACH1 Ser919Pro variant and breast cancer risk.
Vahteristo P; Yliannala K; Tamminen A; Eerola H; Blomqvist C; Nevanlinna H
BMC Cancer; 2006 Jan; 6():19. PubMed ID: 16430786
[TBL] [Abstract][Full Text] [Related]
7. Two Germline Pathogenic Variants in Cancer Susceptibility Genes and Their Null Implication in Breast Cancer Pathogenesis: The Importance of Tumoral Homologous Recombination Deficiency Testing.
Rezqallah A; Torres-Esquius S; Llop-Guevara A; Cruellas M; Martinez MT; Romey M; Denkert C; Serra V; Chirivella I; Balmaña J
JCO Precis Oncol; 2024 Mar; 8():e2300446. PubMed ID: 38513169
[TBL] [Abstract][Full Text] [Related]
8. RAD51C-XRCC3 structure and cancer patient mutations define DNA replication roles.
Longo MA; Roy S; Chen Y; Tomaszowski KH; Arvai AS; Pepper JT; Boisvert RA; Kunnimalaiyaan S; Keshvani C; Schild D; Bacolla A; Williams GJ; Tainer JA; Schlacher K
Nat Commun; 2023 Jul; 14(1):4445. PubMed ID: 37488098
[TBL] [Abstract][Full Text] [Related]
9. Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination.
Setton J; Selenica P; Mukherjee S; Shah R; Pecorari I; McMillan B; Pei IX; Kemel Y; Ceyhan-Birsoy O; Sheehan M; Tkachuk K; Brown DN; Zhang L; Cadoo K; Powell S; Weigelt B; Robson M; Riaz N; Offit K; Reis-Filho JS; Mandelker D
NPJ Breast Cancer; 2021 Oct; 7(1):135. PubMed ID: 34635660
[TBL] [Abstract][Full Text] [Related]
10. CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants.
Carver T; Hartley S; Lee A; Cunningham AP; Archer S; Babb de Villiers C; Roberts J; Ruston R; Walter FM; Tischkowitz M; Easton DF; Antoniou AC
Cancer Epidemiol Biomarkers Prev; 2021 Mar; 30(3):469-473. PubMed ID: 33335023
[TBL] [Abstract][Full Text] [Related]
11. Author Correction: Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress.
Tomaszowski KH; Roy S; Guerrero C; Shukla P; Keshvani C; Chen Y; Ott M; Wu X; Zhang J; DiNardo CD; Schindler D; Schlacher K
Nat Commun; 2024 Mar; 15(1):2214. PubMed ID: 38472265
[No Abstract] [Full Text] [Related]
12. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.
Thompson ER; Boyle SE; Johnson J; Ryland GL; Sawyer S; Choong DY; kConFab ; Chenevix-Trench G; Trainer AH; Lindeman GJ; Mitchell G; James PA; Campbell IG
Hum Mutat; 2012 Jan; 33(1):95-9. PubMed ID: 21990120
[TBL] [Abstract][Full Text] [Related]
13. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
[TBL] [Abstract][Full Text] [Related]
14. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Walsh T; Casadei S; Lee MK; Pennil CC; Nord AS; Thornton AM; Roeb W; Agnew KJ; Stray SM; Wickramanayake A; Norquist B; Pennington KP; Garcia RL; King MC; Swisher EM
Proc Natl Acad Sci U S A; 2011 Nov; 108(44):18032-7. PubMed ID: 22006311
[TBL] [Abstract][Full Text] [Related]
15. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Couch FJ; Hart SN; Sharma P; Toland AE; Wang X; Miron P; Olson JE; Godwin AK; Pankratz VS; Olswold C; Slettedahl S; Hallberg E; Guidugli L; Davila JI; Beckmann MW; Janni W; Rack B; Ekici AB; Slamon DJ; Konstantopoulou I; Fostira F; Vratimos A; Fountzilas G; Pelttari LM; Tapper WJ; Durcan L; Cross SS; Pilarski R; Shapiro CL; Klemp J; Yao S; Garber J; Cox A; Brauch H; Ambrosone C; Nevanlinna H; Yannoukakos D; Slager SL; Vachon CM; Eccles DM; Fasching PA
J Clin Oncol; 2015 Feb; 33(4):304-11. PubMed ID: 25452441
[TBL] [Abstract][Full Text] [Related]
16. Germline RAD51C mutations confer susceptibility to ovarian cancer.
Loveday C; Turnbull C; Ruark E; Xicola RM; Ramsay E; Hughes D; Warren-Perry M; Snape K; ; Eccles D; Evans DG; Gore M; Renwick A; Seal S; Antoniou AC; Rahman N
Nat Genet; 2012 Apr; 44(5):475-6; author reply 476. PubMed ID: 22538716
[No Abstract] [Full Text] [Related]
17. Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Loveday C; Turnbull C; Ramsay E; Hughes D; Ruark E; Frankum JR; Bowden G; Kalmyrzaev B; Warren-Perry M; Snape K; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Brice G; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Shanley S; Walker L; ; Eccles D; Evans DG; Renwick A; Seal S; Lord CJ; Ashworth A; Reis-Filho JS; Antoniou AC; Rahman N
Nat Genet; 2011 Aug; 43(9):879-882. PubMed ID: 21822267
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of small length germline mutations in the RB1 gene.
Lohmann DR; Brandt B; Höpping W; Passarge E; Horsthemke B
Hum Mol Genet; 1994 Dec; 3(12):2187-93. PubMed ID: 7881418
[TBL] [Abstract][Full Text] [Related]
19. RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families.
Schnurbein G; Hauke J; Wappenschmidt B; Weber-Lassalle N; Engert S; Hellebrand H; Garbes L; Becker A; Neidhardt G; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2013 Dec; 15(6):R120. PubMed ID: 24359560
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
